
Chen Yu
QuietNamed in filings at TCG CrossoverOn the current fund
- Board seats filed
- 9

Named in filings at TCG CrossoverOn the current fund
all filings on record
last 24 months
from a verified or cited source
| LB PHARMACEUTICALS | Biotech & pharma | August 2023 | Vida Ventures, Vivo Capital |
| ADARx Pharmaceuticals | Biotech & pharma | August 2023 | Bain Capital Life Sciences, SR One, Vivo Capital |
| Arbor Biotechnologies | Biotech & pharma | October 2021 | ARCH Venture Partners, Novalis Lifesciences Investments, Rogue, Vivo Capital |
| ShouTi | Biotech & pharma | April 2019 | Vivo Capital |
| SentreHEART | Medical devices | September 2016 | Equitage Ventures, U.S Venture Partners, Vivo Capital |
| Kala Pharmaceuticals | Biotech & pharma | April 2016 | Atlas Venture, Lux Capital, Third Rock Ventures, Vivo Capital |
| Outpost Medicine | Biotech & pharma | March 2016 | Frazier Life Sciences, Vivo Capital |
| Nexcida Therapeutics | Biotech & pharma | June 2015 | Frazier Life Sciences, Vivo Capital |
| Nora Therapeutics | Biotech & pharma | April 2014 | Inning One Ventures, Third Rock Ventures, Vivo Capital |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The category is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Categories of companies where filings name Chen Yu on the board, based on 9 filed seats with a verified or cited source.